Pearce IP BioBlast™: w/e 27 November 2020

by , | Dec 1, 2020

22 Nov 20 | Innovent released results of Ph III trials of Tyvyt® (sintilimab) with Byvasda® (biosimilar bevacizumab) as first-line treatment in patients with Advanced Hepatocellular Carcinoma (HCC).

24 Nov 20 | EU | The EMA approved Pfizer’s Nyvepria® (biosimilar pegfilgrastim).

24 Nov 20 | CA | BGP Pharma received a NOC from Health Canada for Hulio® (biosimilar adalimumab).

24 Nov 20 | CN | Alvotech and Alvotech & CCHT Biopharmaceutical announced they have partnered with Yangtze River Pharmaceutical Group to form an exclusive strategic partnership for the commercialisation of eight biosimilar medicines in China.  Alvotech and Alvotech & CCHT will be jointly responsible for the development, registration, and supply of biosimilars in China, while Yangtze River Pharmaceutical will exclusively commercialise them.  The products will be manufactured in a new biopharmaceutical facility currently being built in Changchun, China through the Alvotech & CCHT partnership.

25 Nov 20 | EU | Bio-Thera Solutions announced it has submitted a marketing authorisation application for BAT1706 (proposed bevacizumab biosimilar) in EU.

26 Nov 20 | The Centre for Biosimilars reported on Alvotech’s global biosimilar strategy. Dr Joseph McClellan, Alvotech’s Chief Scientific Officer commented on Alvotech’s long-term expansion plans for global biosimilars markets, suggesting that Alvotech will obtain regulatory approvals for multiple products almost simultaneously in multiple countries before launching.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to recieve our updates via email.

Our Latest News